Kerry Group plc (ISE:KRZ)
Ireland flag Ireland · Delayed Price · Currency is EUR
82.85
-0.25 (-0.30%)
Aug 10, 2026, 4:30 PM GMT

Kerry Group Earnings Call Transcripts

Fiscal Year 2026

  • Strong H1 2026 results featured 3.3% volume growth and 60 bps EBITDA margin expansion, with full-year volume now expected at 3.5%. 2030 targets include 3%-5% volume growth, 20%-21% EBITDA margin, and 12%-13% returns, supported by renovation, innovation, and disciplined capital allocation.

  • Strong H1 results featured 3.3% volume growth, 7.9% constant currency EPS growth, and 60bps EBITDA margin expansion, with broad-based regional gains and robust cash generation. Full-year EPS guidance of 6%-10% constant currency growth is maintained amid ongoing innovation and strategic investments.

  • Status update

    Key 2030 targets include 3%-5% volume growth, 20%-21% EBITDA margins, and high-single-digit EPS growth, driven by food service, emerging markets, and renovation. Integrated technology, digital transformation, and sustainability initiatives underpin continued market outperformance.

  • Q1 2026 saw 3.1% volume growth, strong margin expansion, and continued outperformance in foodservice and retail channels. Guidance for 6%-10% EPS growth is maintained, with input cost inflation expected to return in H2 and currency headwinds moderating.

  • Focused on high single-digit earnings growth, the company leverages innovation, biotechnology, and digital transformation to outperform dynamic food and beverage markets. Strong financial performance, margin expansion, and disciplined capital allocation underpin continued growth and market leadership.

Fiscal Year 2025

  • Delivered strong volume and margin growth in 2025, with robust innovation and strategic investments driving outperformance across regions. Outlook for 2026 includes continued margin expansion, high single-digit EPS growth, and further digital and operational efficiencies.

  • Delivered 3% volume growth and strong EBITDA margin expansion, outperforming end markets. Full-year guidance for adjusted EPS and volume growth reiterated, with robust innovation in food service and private label, and continued investment in biotechnology and digital transformation.

  • Strong H1 results with 3% volume growth and 100 bps EBITDA margin expansion, outpacing flat end markets. Full-year EPS guidance is maintained, with margin outlook raised and volume growth moderated to 3% amid continued innovation and robust cash generation.

  • Q1 2025 saw 3.1% volume growth and 6.3% revenue growth, with strong margin expansion and innovation-led gains in Americas and APMEA, while Europe remained flat. Full-year guidance for 7-11% EPS growth is maintained, with a new EUR 300 million share buyback announced.

  • The company has transformed into a focused taste and nutrition leader, leveraging innovation and sustainability to drive growth. Strong financial performance, robust partnerships, and targeted capital allocation underpin ambitious margin and EPS growth targets through 2028.

Fiscal Year 2024

  • Delivered strong 2024 results with 3.3% volume growth, 120 bps EBITDA margin expansion, and robust cash generation. Outlook for 2025 targets continued outperformance, margin growth, and high single-digit EPS growth, supported by operational efficiencies and innovation.

  • Investor Update

    A €500 million sale of Kerry Dairy Ireland will transform the group into a pure-play B2B taste and nutrition company, boosting EBITDA margins, volume growth, and sustainability metrics, with minimal EPS dilution and improved cash flow conversion. Shareholder approval is required, and the transaction is set to close by January 2025.

  • Q3 saw strong volume growth and margin expansion, led by Foodservice and robust Americas performance. Full-year guidance for 7%-10% adjusted EPS growth is maintained, with continued focus on innovation, capital flexibility, and market penetration opportunities.

  • Investor Day 2024

    Growth is driven by strong performance in the Americas, food service, and emerging markets, with a €15 billion renovation opportunity and integrated technology solutions. Margin expansion to 19–20% is targeted by 2026, supported by high-margin biotechnology and disciplined capital allocation. Sustainability and digital innovation remain key priorities.

  • Strong H1 2024 results with 3.1% T&N volume growth, 6.6% EBITDA increase, and upgraded EPS guidance to 7%-10% growth. Margin expansion, robust cash flow, and strategic investments, including acquisitions and share buybacks, support continued outperformance in key markets.

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Fiscal Year 2018